Schrödinger to Present at Citi Biotech Virtual Co-Panel Day

Rhea-AI Summary

Schrödinger (Nasdaq: SDGR) announced its participation in the Citi Biotech Virtual Co-Panel Day on May 18, 2022, at 10:00 a.m. ET. Karen Akinsanya, president of R&D, Therapeutics, will discuss Software, AI, and Bioinformatics in Drug Development. The panel will be accessible live via the investors section of Schrödinger’s website and will be archived for a week afterward. Schrödinger's innovative software platform significantly enhances the discovery of therapeutics and materials, supporting clients globally since its inception in 1990.

NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate at the Citi Biotech Virtual Co-Panel Day.

Karen Akinsanya, president of R&D, Therapeutics, will participate in a panel discussion about Software, AI, and Bioinformatics in Drug Development which will take place on Wednesday, May 18, 2022, at 10:00 a.m. ET.

The live panel can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately seven days.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 700 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Twitter, or visit our blog, Extrapolations.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220513005071/en/

Jaren Irene Madden

Schrödinger, Inc.

jaren.madden@schrodinger.com

617-286-6264



Tracy Lessor

Schrödinger, Inc.

tracy.lessor@schrodinger.com

617-519-9827

Source: Schrödinger, Inc.

FAQ

What is Schrödinger's upcoming event on May 18, 2022?

Schrödinger will participate in the Citi Biotech Virtual Co-Panel Day, featuring a panel discussion on Software, AI, and Bioinformatics in Drug Development.

Who will represent Schrödinger at the Citi Biotech Virtual Co-Panel Day?

Karen Akinsanya, president of R&D, Therapeutics, will represent Schrödinger on the panel.

How can I access the Citi Biotech Virtual Co-Panel Day panel discussion?

The live panel can be accessed through the 'News & Events' section on Schrödinger's website.

What is the focus of Schrödinger's software platform?

Schrödinger's software platform focuses on transforming the way therapeutics and materials are discovered, enabling faster and cost-effective drug development.

How long will the Citi Biotech Virtual Co-Panel Day panel discussion be available for viewing?

The panel discussion will be archived and available for approximately seven days after the event.